Zobrazeno 1 - 10
of 44
pro vyhledávání: '"rAAV vector"'
Publikováno v:
Analytica, Vol 5, Iss 2, Pp 263-272 (2024)
Rapid advancements in gene technology have raised concerns regarding the potential abuse of techniques, such as gene doping, for enhancing athletic performance. To identify this possibility, a reliable procedure for detecting doping genes is required
Externí odkaz:
https://doaj.org/article/929a629f2e244db09078d6f7746b9b7d
Autor:
Qingyun Zheng, Tianyi Wang, Xiangying Zhu, Xiao Tian, Chen Zhong, Guolin Chang, Gai Ran, Yilin Xie, Bing Zhao, Liqing Zhu, Chen Ling
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss , Pp 293-303 (2021)
The major challenge of recombinant adeno-associated virus (rAAV) vectors is host immunological barriers. Compared to the neutralizing antibody and the cytotoxic T lymphocyte response, the host immune responses induced by unsatisfactory rAAV manufactu
Externí odkaz:
https://doaj.org/article/3a3bb4272fd348898a6be51f1a71a71e
Autor:
Gai Ran, Xiao Chen, Yilin Xie, Qingyun Zheng, Jinyan Xie, Chenghui Yu, Nikea Pittman, Sixian Qi, Fa-Xing Yu, Mavis Agbandje-McKenna, Arun Srivastava, Chen Ling
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 17, Iss , Pp 545-555 (2020)
Recombinant adeno-associated virus (rAAV) vectors selected from capsid libraries present enormous advantages in high selectivity of tissue tropism and their potential use in human gene therapy applications. For example, rAAV-LK03, was used in a gene
Externí odkaz:
https://doaj.org/article/b38a05093c5a4598a4a393131cc871b5
Publikováno v:
Pharmaceuticals, Vol 16, Iss 4, p 624 (2023)
Krabbe disease is a rare neurodegenerative fatal disease. It is caused by deficiency of the lysosomal enzyme galactocerebrosidase (GALC), which results in progressive accumulation of galactolipid substrates in myelin-forming cells. However, there is
Externí odkaz:
https://doaj.org/article/0b15937909d4498f8982ff1e167d90da
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ruth Rieser, Johanna Koch, Greta Faccioli, Klaus Richter, Tim Menzen, Martin Biel, Gerhard Winter, Stylianos Michalakis
Publikováno v:
Pharmaceutics, Vol 13, Iss 5, p 748 (2021)
Recombinant adeno-associated virus (rAAV) vectors have evolved as one of the most promising technologies for gene therapy due to their good safety profile, high transduction efficacy, and long-term gene expression in nondividing cells. rAAV-based gen
Externí odkaz:
https://doaj.org/article/34815d04c6634e498a6c77739a3c1b86
Autor:
Xiao Tian, Chen Ling, Bing Zhao, Liqing Zhu, Gai Ran, Xiangying Zhu, Qingyun Zheng, Guolin Chang, Chen Zhong, Tianyi Wang, Yilin Xie
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 22, Iss, Pp 293-303 (2021)
The major challenge of recombinant adeno-associated virus (rAAV) vectors is host immunological barriers. Compared to the neutralizing antibody and the cytotoxic T lymphocyte response, the host immune responses induced by unsatisfactory rAAV manufactu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d224f5e812facd41c9456766626beb2
https://doi.org/10.1016/j.omtm.2021.06.009
https://doi.org/10.1016/j.omtm.2021.06.009
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stylianos Michalakis, Martin Biel, Johanna Koch, Greta Faccioli, Ruth Rieser, Klaus Richter, Tim Menzen, Gerhard Winter
Publikováno v:
Pharmaceutics
Volume 13
Issue 5
Pharmaceutics, Vol 13, Iss 748, p 748 (2021)
Volume 13
Issue 5
Pharmaceutics, Vol 13, Iss 748, p 748 (2021)
Recombinant adeno-associated virus (rAAV) vectors have evolved as one of the most promising technologies for gene therapy due to their good safety profile, high transduction efficacy, and long-term gene expression in nondividing cells. rAAV-based gen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d39ff08bbe5e92ba9057a859a33aa4a
Autor:
Qingyun, Zheng, Tianyi, Wang, Xiangying, Zhu, Xiao, Tian, Chen, Zhong, Guolin, Chang, Gai, Ran, Yilin, Xie, Bing, Zhao, Liqing, Zhu, Chen, Ling
Publikováno v:
Molecular Therapy. Methods & Clinical Development
The major challenge of recombinant adeno-associated virus (rAAV) vectors is host immunological barriers. Compared to the neutralizing antibody and the cytotoxic T lymphocyte response, the host immune responses induced by unsatisfactory rAAV manufactu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c3f5f3197024ff81a113e9d2ee069002
https://pubmed.ncbi.nlm.nih.gov/34485612
https://pubmed.ncbi.nlm.nih.gov/34485612